Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study

Abstract Cyclophosphamide (CPA) dosing by body surface area (BSA, m2) has been questioned as a predictor for individual drug exposure. This study investigated phosphoramide mustard-hemoglobin (PAM-Hb, pmol g−1 Hb) as a biomarker of CPA exposure in 135 female breast cancer patients receiving CPA duri...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	S. A. M. Gernaat, H. von Stedingk, M. Hassan, H. P. Nilsson, K. A. Rodriguez-Wallberg, E. Hedayati, P. Rydberg
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4da5692c7f0b46adbbcf22da4b21fe1a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4da5692c7f0b46adbbcf22da4b21fe1a
record_format	dspace
spelling	oai:doaj.org-article:4da5692c7f0b46adbbcf22da4b21fe1a2021-12-02T14:06:51ZCyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study10.1038/s41598-021-81662-12045-2322https://doaj.org/article/4da5692c7f0b46adbbcf22da4b21fe1a2021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-81662-1https://doaj.org/toc/2045-2322Abstract Cyclophosphamide (CPA) dosing by body surface area (BSA, m2) has been questioned as a predictor for individual drug exposure. This study investigated phosphoramide mustard-hemoglobin (PAM-Hb, pmol g−1 Hb) as a biomarker of CPA exposure in 135 female breast cancer patients receiving CPA during three courses based on BSA: 500 mg/m2 (C500 group, n = 67) or 600 mg/m2 (C600 group, n = 68). The inter-individual difference was calculated for both groups by dividing the highest through the lowest PAM-Hb value of each course. The inter-occasion difference was calculated in percentage for each individual by dividing their PAM-Hb value through the group mean per course, and subsequently dividing this ratio of the latter through the previous course. A multivariable linear regression (MLR) was performed to identify factors that explained the variation of PAM-Hb. During the three courses, the inter-individual difference changed from 3.5 to 2.1 and the inter-occasion difference ranged between 13.3% and 11.9% in the C500 group. In the C600 group, the inter-individual difference changed from 2.7 to 2.9 and the inter-occasion difference ranged between 14.1% and 11.7%. The MLR including BSA, age, GFR, and albumin explained 17.1% of the variation of PAM-Hb and was significantly better then the model including only BSA. These factors should be considered when calculating the first dose of CPA for breast cancer patients.S. A. M. GernaatH. von StedingkM. HassanH. P. NilssonK. A. Rodriguez-WallbergE. HedayatiP. RydbergNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q S. A. M. Gernaat H. von Stedingk M. Hassan H. P. Nilsson K. A. Rodriguez-Wallberg E. Hedayati P. Rydberg Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study
description	Abstract Cyclophosphamide (CPA) dosing by body surface area (BSA, m2) has been questioned as a predictor for individual drug exposure. This study investigated phosphoramide mustard-hemoglobin (PAM-Hb, pmol g−1 Hb) as a biomarker of CPA exposure in 135 female breast cancer patients receiving CPA during three courses based on BSA: 500 mg/m2 (C500 group, n = 67) or 600 mg/m2 (C600 group, n = 68). The inter-individual difference was calculated for both groups by dividing the highest through the lowest PAM-Hb value of each course. The inter-occasion difference was calculated in percentage for each individual by dividing their PAM-Hb value through the group mean per course, and subsequently dividing this ratio of the latter through the previous course. A multivariable linear regression (MLR) was performed to identify factors that explained the variation of PAM-Hb. During the three courses, the inter-individual difference changed from 3.5 to 2.1 and the inter-occasion difference ranged between 13.3% and 11.9% in the C500 group. In the C600 group, the inter-individual difference changed from 2.7 to 2.9 and the inter-occasion difference ranged between 14.1% and 11.7%. The MLR including BSA, age, GFR, and albumin explained 17.1% of the variation of PAM-Hb and was significantly better then the model including only BSA. These factors should be considered when calculating the first dose of CPA for breast cancer patients.
format	article
author	S. A. M. Gernaat H. von Stedingk M. Hassan H. P. Nilsson K. A. Rodriguez-Wallberg E. Hedayati P. Rydberg
author_facet	S. A. M. Gernaat H. von Stedingk M. Hassan H. P. Nilsson K. A. Rodriguez-Wallberg E. Hedayati P. Rydberg
author_sort	S. A. M. Gernaat
title	Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study
title_short	Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study
title_full	Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study
title_fullStr	Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study
title_full_unstemmed	Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study
title_sort	cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: the tailordose i study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4da5692c7f0b46adbbcf22da4b21fe1a
work_keys_str_mv	AT samgernaat cyclophosphamideexposureassessedwiththebiomarkerphosphoramidemustardhemoglobininbreastcancerpatientsthetailordoseistudy AT hvonstedingk cyclophosphamideexposureassessedwiththebiomarkerphosphoramidemustardhemoglobininbreastcancerpatientsthetailordoseistudy AT mhassan cyclophosphamideexposureassessedwiththebiomarkerphosphoramidemustardhemoglobininbreastcancerpatientsthetailordoseistudy AT hpnilsson cyclophosphamideexposureassessedwiththebiomarkerphosphoramidemustardhemoglobininbreastcancerpatientsthetailordoseistudy AT karodriguezwallberg cyclophosphamideexposureassessedwiththebiomarkerphosphoramidemustardhemoglobininbreastcancerpatientsthetailordoseistudy AT ehedayati cyclophosphamideexposureassessedwiththebiomarkerphosphoramidemustardhemoglobininbreastcancerpatientsthetailordoseistudy AT prydberg cyclophosphamideexposureassessedwiththebiomarkerphosphoramidemustardhemoglobininbreastcancerpatientsthetailordoseistudy
_version_	1718391961111494656

Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study

Ejemplares similares